このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effectiveness of Resistance Exercises Added to Aerobic and Balance Exercises in Parkinson's Disease

2026年7月26日 更新者:Nazlı İlgüner、Sisli Hamidiye Etfal Training and Research Hospital

The Effects of Resistive Exercises Added to Aerobic and Balance Exercises on Quality of Life, Activities of Daily Living, Cognitive Functions, and Sarcopenia Parameters in Patients With Early-Stage Parkinson's Disease: A Prospective Randomized Controlled Study.

The purpose of this study is to evaluate the effects of resistive exercises added to aerobic and balance exercises on quality of life, activities of daily living, cognitive functions, and sarcopenia parameters in patients diagnosed with early-stage PD. The main question it aims to answer is: In patients diagnosed with early-stage Parkinson's disease, do resistive exercises added to aerobic and balance exercises have an effect on quality of life, daily living activities, cognitive function, and sarcopenia parameters? If so, what is the nature of this effect? Patients will undergo an exercise program three days a week for eight weeks. Outcomes will be assessed at baseline, on the first day after the treatment and 4 weeks after the end of the treatment.

調査の概要

詳細な説明

Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigidity, resting tremor and postural instability. It can lead to numerous motor, neuropsychiatric, cognitive, and autonomic symptoms. In advanced stages, it can increase the risk of falling by causing postural instability. Sarcopenia is characterized by a decrease in muscle mass and function. Sarcopenia prevalence increases with age, leading to increased fragility and risk of falling. Studies have shown that various exercise programs, including aerobic, balance, and resistive exercises, have positive effects on rigidity, tremor, gait disorders, and physical capacity in patients diagnosed with PD. The purpose of this study is to evaluate the effects of resistive exercises added to aerobic and balance exercises on quality of life, activities of daily living, cognitive functions, and sarcopenia parameters in patients diagnosed with early-stage PD.

Adults who aged between 40-70 years, diagnosed with PD and meet predefined inclusion and exclusion criteria will be enrolled and randomly assigned to one of two exercise based treatment groups. Both groups will receive aerobic and balance exercises, while one group will additionaly receive resistive exercises. Both groups will undergo exercise programs three days a week for eight weeks. Evaluations will be conducted using the The Parkinson's Disease Questionnaire-39 (PDQ-39), Short Physical Performance Battery (SPPB), SARC-F Questionnaire, Berg Balance Test, Katz Index of Independence in Activities of Daily Living, Montreal Cognitive Assesment (MoCA), Patient Health Questionnaire-9 (PH-9), functional performance tests, grip strentgh measurements and quadriceps muscle thickness measurement via ultrasonography. Evaluations will be performed at baseline, on the first day after the treatment and 4 weeks after the end of the treatment.

研究の種類

介入

入学 (実際)

34

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Adults aged 40 to 70 years
  • Patients diagnosed with Modified Hoehn-Yahr stage 1-3 Parkinson's disease
  • Patients diagnosed with Parkinson's disease for more than 1 year
  • Patients who can mobilize without an assistive device

Exclusion Criteria:

  • Patients diagnosed with Parkinson Plus syndrome
  • History of uncontrolled hypertension
  • History of uncontrolled diabetes mellitus
  • History of serebrovascular disease within the past 6 months
  • History of miyocardial infarction within the past 6 months
  • History of knee or hip artroplasty surgery
  • History of severe cardiac arrythmia
  • Presence of cardiac pacemaker
  • Presence of severe dementia
  • History of severe psychiatric disorders
  • Patients who have on dialysis
  • Presence of acute infection
  • Pregnancy
  • History of malignancy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Aerobic and Balance Exercise Group
Participants will receive an exercise program with 3 days a week for 8 weeks. Each treatment session will not exceed 45 minutes. Program will include aerobic exercises with 15 minutes on a treadmill, aiming not to exceed 85% of maximum heart rate and balance exercises including tandem stance, tandem walk, side stepping, backward walking, single leg stance.
An 3 days a week for 8 weeks aerobic and balance exercises program
他の名前:
  • Aerobic and Balance Exercises
A 3 days a week for 8 weeks aerobic, balance and resistive exercises program
他の名前:
  • Aerobic, Balance and Resistive Exercises
実験的:Aerobic, Balance and Resistive Exercise Group
Participants will receive an exercise program with 3 days a week for 8 weeks. Each treatment session will not exceed 45 minutes. Program will include aerobic exercises with 15 minutes on a treadmill, aiming not to exceed 85% of maximum heart rate; balance exercises including tandem stance, tandem walk, side stepping, backward walking, single leg stance and resistive exercises for upper and lower extremity
An 3 days a week for 8 weeks aerobic and balance exercises program
他の名前:
  • Aerobic and Balance Exercises
A 3 days a week for 8 weeks aerobic, balance and resistive exercises program
他の名前:
  • Aerobic, Balance and Resistive Exercises

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Grip strenght
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Grip strength is measured using a hydraulic hand dynamometer with the dominant hand.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Chair Stand Test
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Chair Stand Test is used to assess muscle function. Patients asked to sit and stand on a chair for 5 times.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Gait Speed
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Gait speed is assessed by measuring the time it takes the patient to walk a distance of 4 meters.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Quadriceps Muscle Thickness Measurement
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Quadriceps muscle thickness measurement is performed ultrasonographically with a linear probe, without compression, with the patient in the supine position, from the anterior side, at the midpoint of the linear line passing between the anterior superior iliac spine (ASIS) and the upper pole of the patella.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Time-Up And Go Test
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
It is measured by the time it takes for a person to get up from their chair, walk 3 meters, return, and sit back down.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
SARC-F Questionnaire
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
SARC-F is a screening tool to identify propable sarcopenic patients. The total score ranges from 0 to 10; a score of 4 or higher indicates a risk of sarcopenia.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Short Physical Performance Battery (SPPB)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Short Physical Performance Battery (SPPB) is a assessment tool for evaluating physical performance. The total score ranging from 0 to 12 where 0 indicates worst performance and 12 indicates best performance.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Berg Balance Scale
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Berg Balance Scale is a 14-item test used to evaluate functional balance and fall risk in patiens. Each item is scored on a 0-4 scale. The total score is ranging 0 to 56 where lower scores indicates higher fall risk.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Parkinson's Disease Questionnaire-39 (PDQ-39)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Parkinson's Disease Questionnaire-39 (PDQ-39) is used to assess quality of life among with patients with Parkinson's disease. The scale consists of 39 multiple-choice items covering 8 factors. Each question is scored between 0 and 4. Higher scores indicate a deterioration in quality of life.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Patient Health Questionnaire (PHQ)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Patient Health Questionnaire-9 (PHQ-9) is diagnostic and screening tool for depression. The PHQ-9 measures symptoms over the past 2 weeks on a scale of 0 (not at all) to 3 (nearly every day). Total score ranges 0 to 27.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Katz Index of Independence in Activities of Daily Living
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
Katz Index of Independence in Activities of Daily Living is used to assess basic functional status and the level of independency. The total score ranging from 0 to 6, where 0 indicates severe functional impairment and 6 indicates full function.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Montreal Cognitive Assessment (MoCA)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
The Montreal Cognitive Assessment (MoCA) is used to detect cognitive impairment. The total score ranges 0 to 30 which scores of 26 to 30 are generally considered normal cognitive function.
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月1日

一次修了 (実際)

2026年6月15日

研究の完了 (実際)

2026年6月15日

試験登録日

最初に提出

2026年6月1日

QC基準を満たした最初の提出物

2026年6月1日

最初の投稿 (実際)

2026年6月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月28日

QC基準を満たした最後の更新が送信されました

2026年7月26日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared, as this is a single-center, academic study, and there is no plan or requirement to make the raw dataset publicly available.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する